ALSO NOTED: New doubts on Arcoxia; Pharmacopeia bullish on early data; Ammon retires from Endo; and much more...

> Raising fresh doubts about the prospects of Merck's Arcoxia when it goes in front of an FDA panel on Thursday, the agency released its opinion that the only NSAIDs that should be approved now would have to fill an unmet medical need where no safe alternative exists. Report

> Pharmacopeia Drug Discovery sounded a bullish note on early data for an experimental therapy for hypertension and diabetic nephropathy. Report

> Chutes & Ladders: Carol Ammon, the founder and chairwoman of Endo Pharmaceuticals, plans to retire and focus on philanthropy. Article

> The Medical University of South Carolina has begun construction of a new drug research facility. Report

> Orexigen Therapeutics has set the terms for its IPO at 6 million shares priced at $11 to $13 per share. Report

> J&J is recalling a prescription drug for fungal infections after finding fragments of glass in bottles of the therapy. Report

> Researchers at Duke University say that family members that smoked and drank coffee were less likely to develop Parkinson's disease. Report

> The NIAID will spend $23 million a year over the next seven years to establish a consortium of six research centers to investigate influenza viruses--including H5N1. Report

And Finally... GSK has turned to an auto company for research ideas. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.